GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Addex Therapeutics ADXN · USD

Health Care · US listing · 🇺🇸 United States

Compare

2.79

-3.79%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$35,894

FY2016FY2025

Net income

−$8.1m

FY2016FY2025

Free cash flow

−$2.5m

FY2016FY2025

Shareholders' equity

$5.7m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$35,894$483,947$1.9m$1.7m$3.5m$4.3m$3.3m$7.2m$598,667$20,753
Gross profit$35,894$483,947$1.9m$1.7m$3.5m$4.3m$3.0m$7.1m$563,022−$488,120
Research and development$227,769$521,177$1.1m$9.4m$10.8m$12.4m$14.9m$2.8m$1.0m$981,219
Operating income−$8.2m−$3.3m−$2.7m−$12.9m−$18.6m−$15.4m−$17.5m−$1.7m−$3.9m−$3.8m
Net income−$8.1m$8.4m−$12.6m−$24.9m−$18.4m−$15.4m−$17.7m−$2.0m−$3.9m−$3.8m
Diluted earnings per share-6.790.09-15.93-50.08-63.44-69.02-4.01-8.88-35.23-38.57

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$7.6m$12.8m$5.6m$9.9m$27.0m$24.2m$39.6m$50.6m$3.7m$2.0m
Cash and short-term investments$2.0m$4.0m$4.6m$8.3m$24.6m$22.5m$37.8m$49.9m$3.1m$1.7m
Total liabilities$1.9m$1.2m$4.2m$4.0m$6.7m$6.7m$9.0m$3.6m$2.1m$1.8m
Debt$41,589$50,291$412,372$446,862$577,254$679,506$658,967$17,869$13,148—
Shareholders' equity$5.7m$11.6m$1.4m$5.9m$20.3m$17.5m$30.6m$47.0m$1.6m$261,783
Shares outstanding1m98m1m0m0m0m4m0m0m0m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−$2.5m−$6.4m−$9.6m−$19.7m−$17.6m−$14.6m−$11.4m$2.1m−$2.6m−$3.2m
Capital spending—−$1,525−$8,194−$696−$37,783−$71,153−$34,082−$10,843−$835−$13,438
Free cash flow−$2.5m−$6.4m−$9.6m−$19.7m−$17.6m−$14.7m−$11.4m$2.1m−$2.6m−$3.2m
Dividends paid———−$368,253−$467,285—————

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-72.4%-61.6%-2.9%
Operating income-14.1%-11.8%5.9%
Net income-31.4%-12.2%4.8%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin100.0%100.0%100.0%95.7%
Operating margin-2210.5%-651.8%-509.5%-399.0%
Net margin75.5%-894.5%-592.5%-445.7%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020
Price to earnings-1.181.5-0.2-0.1-0.4-0.8
Price to sales255.1—1.21.72.22.9

Share price return

Finished calendar years

202520242023202220212020
Return2%202%-55%-80%-8%11%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.